Enovis (NYSE:ENOV) Reaches New 52-Week Low – Here’s What Happened

Enovis Corporation (NYSE:ENOV) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $18.50 and last traded at $18.70, with a volume of 127204 shares traded. The stock had previously closed at $19.03.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENOV. Citigroup reissued a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Evercore set a $32.00 price objective on Enovis in a research note on Monday, July 6th. Canaccord Genuity Group lowered their target price on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, August 17th. UBS Group reaffirmed a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Saturday. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.38.

Enovis Price Performance

The company has a 50 day moving average price of $25.25 and a 200 day moving average price of $24.10. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The firm has a market cap of $1.13 billion, a PE ratio of -1.01 and a beta of 1.31.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same quarter last year, the firm earned $0.79 earnings per share. The firm’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert acquired 2,660 shares of the business’s stock in a transaction on Friday, September 4th. The stock was purchased at an average price of $18.80 per share, for a total transaction of $50,008.00. Following the completion of the transaction, the insider owned 63,898 shares of the company’s stock, valued at $1,201,282.40. The trade was a 4.34% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders purchased 24,293 shares of company stock worth $470,519. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Large investors have recently made changes to their positions in the stock. Rubric Capital Management LP acquired a new stake in shares of Enovis in the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY purchased a new position in Enovis in the 2nd quarter valued at approximately $28,533,000. California State Teachers Retirement System raised its holdings in Enovis by 1,635.6% during the second quarter. California State Teachers Retirement System now owns 1,335,833 shares of the company’s stock worth $27,652,000 after purchasing an additional 1,258,867 shares during the last quarter. Bank of America Corp DE acquired a new position in Enovis during the second quarter worth $11,502,000. Finally, AQR Capital Management LLC boosted its position in Enovis by 682.6% during the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.